Thymosin alpha-1 (Zadaxin) in extended/chronic administration research protocols — distinct from standard acute infection courses. Studied for long-term immunosenescence reversal, chronic viral infection suppression, and longevity applications in aging immune systems.
2 hours; extended protocol compensates via frequent dosing (3x/week or daily)
SKUs
1
Evidence
Moderate Evidence
TA-1 Extended refers to extended or modified formulations of Thymosin Alpha-1 (TA1), a naturally occurring peptide produced by the thymus gland. Standard Thymosin Alpha-1 (thymalin's more specific counterpart) is FDA-approved in many countries as Zadaxin for various immune conditions. Extended or modified versions aim to improve the short half-life of the native peptide through formulation strategies.
Immune System Support Research
Thymosin Alpha-1 has been studied extensively for immune modulation. It enhances T-cell maturation and function, increases natural killer cell activity, and modulates cytokine production. Clinical evidence supports its use in hepatitis B and C, HIV, and as an immune adjuvant with vaccines.
Infectious Disease Research
TA1 has been studied in sepsis, influenza, and COVID-19 contexts. Some COVID-19 trials showed improvements in outcomes in severe cases, though larger confirmatory trials are needed. It has been used in severe sepsis protocols in some countries.
Cancer Immunotherapy Research
TA1 has been studied alongside cancer chemotherapy to support immune function and reduce treatment-related immunosuppression. Some studies show improvements in treatment tolerance and immune markers.
Extended Formulation Research
Standard TA1 has a half-life of approximately two hours, requiring frequent dosing. Extended-release or PEGylated formulations are in development to allow less frequent administration while maintaining sustained immune-supporting activity.
Standard TA1 approved in over 30 countries for hepatitis and immune support.
Clinical evidence for immune enhancement in multiple infectious disease and cancer contexts.
Some COVID-19 trial evidence for severe case outcomes.
Extended formulation research is ongoing — specific TA1-Extended data are limited.
Well-characterized mechanism through T-cell maturation and activation pathways.
TA1-Extended as a specific extended formulation has limited published clinical data separate from standard TA1. The evidence base is primarily for standard TA1. Not FDA-approved in the US (though approved in many other countries as Zadaxin). Extended formulation-specific pharmacokinetics and dosing are not established in large trials.
The thymus gland trains immune cells by exposing T-cell precursors to thymic peptides that help them mature into functional T-cells capable of recognizing threats without attacking the body's own tissue. Thymosin Alpha-1 is one of the key thymic peptides involved in this training process. When administered, it activates dendritic cells and T-cells, enhancing their ability to identify and respond to infections and abnormal cells. It works primarily by activating toll-like receptor signaling pathways that put the immune system into a more alert state. Extended formulations aim to keep these activating signals present for longer periods without the need for daily dosing.
Standard Thymosin Alpha-1 has an excellent safety record from decades of clinical use in over 30 countries. It is generally very well-tolerated with minimal side effects. Extended formulations carry the safety expectations of the base compound, with additional monitoring needed for the formulation technology used. Not FDA-approved in the US.
Moderate Evidence
This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.
Published Research Ranges
1.6–3.2mg SC, 3x/week or daily for 6–12 month extended protocols in aging/chronic disease research
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B
The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.